Opnext Demonstrates First Real-Time Coherent 100G Field Trial in Europe

Opnext reported that it has demonstrated a real-time coherent modem on the network of TeliaSonera in Sweden. The trial of the single wavelength 127G PM-QPSK (Polarization Multiplexed Quadrature Phase Shift Keying) modem represents first of its kind in Europe on a 100G field.

The trial was performed on a haul link that ran between Uppsala and Olofström in Sweden for a total distance of 1700 km with a mixed traffic of 10 and 40 Gbps. This makes it the longest real-time, un-generated trial ever conducted.

The implementation of the 100 Gbps technology in the transmission channel did not call for optimization. This reaffirms the user-friendliness of the company’s coherent technology. Nowadays many 10 and 40 Gbps systems that use direct detection need optimization and balancing of optical impairments on installed optical fiber. The plug and play technology from the company enables the carriers to enhance the line systems with 100 Gbps capability, without modifying the current network.

Further, the new optical systems with Opnext technology have the ability to avoid external dispersion compensation, which in turn reduces IP latency, enables deployment on older installed optical fiber and minimizes cost.

The Head of TeliaSonera’s Broadband Development division Staffan Göjeryd commented that the trial demonstrated their focus on sustaining an advanced network that can readily use future technologies. The President of Opnext’s Subsystems division Mike Chan denoted the importance of 100G modem performance in assisting carriers to match the increased bandwidth demands from their customers. This trial brings the optical telecommunication industry more close to the 100G technology commercialization, he added.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.